Why the study?
Does elevated heparanase (HPA) level predict high thrombus burden and thrombotic complications in patients with STEMI?
Does elevated heparanase (HPA) level predict high thrombus burden and thrombotic complications in patients with STEMI?
Heparanase levels may serve as a predictive biomarker for high thrombus burden and no-reflow phenomenon in patients presenting with STEMI.
Answers are grounded in this paper and cite their sources.
HPA may aid STEMI thrombus risk assessment; hypothesis-generating and should not change practice without prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gürbüz et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: